New advances in gene editing, such as CRISPR-Cas9 technology, open new and exciting avenues for genome-scale functional interrogation of the genome. The newly formed Functional Genomics department (FxG) at GSK exists to provide the deep scientific knowledge and technical capabilities required to reveal genetic clues that underpin human disease, ultimately providing better medicines for our patients. Our High Throughput Biology and Imaging (HTBI) group in FxG has designed and built a high throughput automated robotic platform to interrogate drug and genetic interactions (DrugxDrug, DrugxGene and GenexGene) at scale by using cell-based high content imaging, flow cytometry and plate reader screening assays. The group is formed by a multidisciplinary team of scientists, including assay development and high content imaging experts, computational scientists and automation engineers. Our primary goal is to use functional genomics approaches for predicting and identifying new oncology combination therapies, and immuno-oncology mechanistic insights of GSK assets mode of action by interrogating gene function using RNAi and CRISPR/Cas9 genome wide array screening. The presentation will have examples on a couple of projects we are currently working on highlighting the potential benefits to run a functional genomics screening at scale.